ClinicalImpact™ Melanoma: Expert Guidance and Resources to Optimize Care Along the Treatment Continuum

Download All
This comprehensive program gathers expert insights into best practice management of patients with melanoma, featuring expert-authored commentaries on timely topics in melanoma, a series of focused MedicalMinute™ videos to fit your busy schedule, and downloadable slides from a live Webinar.
person default
Allison Betof Warner, MD, PhD
Michael A. Davies, MD, PhD
Douglas B. Johnson, MD, MSCI
Ahmad Tarhini, MD, PhD

ClinicalThought

How do you choose among approved adjuvant therapies for BRAF V600E/K high-risk melanoma? Read my thoughts on factors to consider when selecting adjuvant targeted therapy for your patients.

Douglas B. Johnson, MD, MSCI Released: October 19, 2020

Here are my thoughts on key considerations when selecting frontline therapy for patients with metastatic melanoma, including when targeted therapy may be preferred over immunotherapy, factors that affect the selection of single-agent or combination immunotherapy, and when to discontinue immunotherapy.

person default Allison Betof Warner, MD, PhD Released: February 17, 2021

Experts answer frequently asked questions on the management of melanoma, including adjuvant therapy selection, considerations for frontline treatment, and biomarker testing.

Michael A. Davies, MD, PhD Ahmad Tarhini, MD, PhD Released: March 3, 2021
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Bristol-Myers Squibb
Novartis Pharmaceuticals Corporation

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue